Catalyst Event
Hansoh Pharmaceutical Group Company Limited (3692) · Other
From Akros SCHK HK-U.S. Tech 100 Index (ASHUSTC)
5/9/2026, 12:00:00 AM
HS-20093 granted Breakthrough Therapy Designation by China's NMPA for esophageal squamous cell carcinoma on 2026-05-09; estimated 5% impact from accelerated approval path.
Korean Translation
2026-05-09, HS-20093의 식도 편평세포암 혁신 치료제 지정됨. 승인 절차 가속화로 약 5%의 주가 영향이 예상됨.
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
Microsoft Corp (MSFT) · Earnings Release
Microsoft is scheduled to report its Q4 and full-year fiscal 2026 earnings results on 2026-07-28, with analysts forecasting EPS around $4.24-$4.33. High importance is estimated due to typical 10% price volatility following earnings scheduled.
7/28/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Other
AMD's 'Advancing AI 2026' event to detail future AI product roadmaps on July 23, 2026 is expected to have a 5% price impact scheduled.
7/23/2026, 12:00:00 AM
Amphenol Corp (APH) · Earnings Release
Next quarterly earnings release for Q2 2026 is a routine administrative event with low expected impact, scheduled.
7/22/2026, 12:00:00 AM
Thermo Fisher Scientific Inc (TMO) · Earnings Release
Q2 2026 earnings release scheduled for 2026-07-22; low importance estimated as earnings typically cause moderate volatility, expected.
7/22/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM